Literature DB >> 6591852

Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography.

C M Myers, J L Blumer.   

Abstract

Imipenem and cilastatin concentrations in serum were determined by using reverse-phase high-pressure liquid chromatography. Serum samples were stabilized with 0.5 M morpholineethanesulfonic acid buffer (pH 6.0) and subjected to ultrafiltration before chromatography. The elution solvent consisted of water or potassium phosphate buffered to pH 2.5 and methanol. The imipenem and cilastatin peaks were detected at 300 and 220 nm, respectively. Recovery from serum was 99% for both imipenem and cilastatin, and the limits of detectability for the two compounds were 0.3 and 0.5 microgram/ml, respectively. The assay may be readily applied to pharmacokinetic analysis of imipenem and cilastatin biodisposition in patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6591852      PMCID: PMC179921          DOI: 10.1128/AAC.26.1.78

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species.

Authors:  M H RIchmond
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

2.  The antibacterial activity of thienamycin against multiresistant bacteria-comparison with beta-lactamase stable compounds.

Authors:  M F Romagnoli; K P Fu; H C Neu
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

Authors:  S R Norrby; K Alestig; F Ferber; J L Huber; K H Jones; F M Kahan; M A Meisinger; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

4.  Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

Authors:  S R Norrby; K Alestig; B Björnegård; L A Burman; F Ferber; J L Huber; K H Jones; F M Kahan; J S Kahan; H Kropp; M A Meisinger; J G Sundelof
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

5.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

8.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  8 in total
  15 in total

1.  Radiolabeled quaternary carbapenems and their interactions with human serum albumin.

Authors:  K T Ogborne; M J Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

2.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Degradation kinetics of imipenem in normal saline and in human serum.

Authors:  D J Swanson; C DeAngelis; I L Smith; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Determination of imipenem and cilastatin in serum and tissue by high-pressure liquid chromatography.

Authors:  R Krausse; U Ullmann
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

5.  Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life.

Authors:  M D Reed; R M Kliegman; T S Yamashita; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice.

Authors:  Lorna E T Stearne; Steven L Buijk; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

7.  Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).

Authors:  M C Vos; H H Vincent; E P Yzerman
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 8.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

9.  Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; C A O'Brien; T S Yamashita; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

10.  Single-dose pharmacokinetics of imipenem-cilastatin in neonates.

Authors:  W C Gruber; M A Rench; J A Garcia-Prats; M S Edwards; C J Baker
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.